AstraZeneca
AstraZeneca
One-line summary: Global large-cap pharma (NASDAQ ADR: AZN); tracked here across three threads — the eplontersen ATTR-CM null (loser), a fast-follower oral PCSK9 (macrocyclic peptide), and a July 2026 in-license of Dizal's EGFR-exon20 inhibitor sunvozertinib to extend its dominant EGFR franchise.
What it is
AstraZeneca is a diversified global pharma with a dominant oncology EGFR franchise (Tagrisso/osimertinib, >$7B sales). It also runs cardiometabolic programs (the Ionis-partnered eplontersen) and is developing an oral PCSK9 for cholesterol.
Why it matters to stock-market
AZN appears on multiple healthcare nodes: it is the marketing partner on the failed eplontersen (see eplontersen-failure-to-alnylam-silencer-consolidation, where AZN fell ~10% on the day), a fast-follower in oral-pcsk9-class-disruption, and the acquirer of tuck-in EGFR optionality via the Dizal license — the "800-pound gorilla" consolidating its own therapeutic area.
Key facts
- Dizal / sunvozertinib license (July 2026). AZN licensed Dizal's EGFR exon-20 inhibitor sunvozertinib — $600M upfront, up to $900M development milestones. AZN already holds an equity stake in Dizal. sam-facelli in 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026: the data "does stack up" vs competitors (Cullinan, Arrivent, Hansoh) and against J&J's Rybrevant bispecific, "the side effect profile looks easier to manage," and "astra is the ideal partner here... given that they have the broader EGFR space." Small indication, marketed in China and "doing relatively well."
- Oral PCSK9 fast-follower. Following Merck's Lipfendra with a macrocyclic-peptide oral PCSK9 that binds PCSK9 and blocks LDL-receptor interaction; ambition to combine it with AZN's oral obesity drug (possibly fixed-dose). From 2026-07-17-podcast-biotech-hangout-episode-189-july-17-2026.
- Eplontersen ATTR-CM null (w/ ionis): total null on background tafamidis; AZN −10% on the day. See eplontersen-failure-to-alnylam-silencer-consolidation.
Open questions
- Does the oral-obesity + oral-PCSK9 combination materialize as a differentiated cardiometabolic play, or is john-maraganore's once-yearly PCSK9 siRNA the better prevention expression?